Elkind-Hirsch K E, Platia M P, Schiff I
J Reprod Med. 1987 Jan;32(1):5-9.
There is evidence to suggest that abnormalities in the secretion of prolactin (PRL) in patients with the hyperprolactinemia-amenorrhea syndrome are due to hypothalamic dysfunction. In an attempt to further define the inhibitory effect of excessive PRL release on luteinizing hormone releasing hormone (LHRH) and luteinizing hormone (LH) secretory patterns in human plasma, four amenorrheic women with known hyperprolactinemia were studied before and during bromocriptine (BRCR) therapy. Ten-minute blood samples collected with a continuous withdrawal pump for two hours were analyzed for immunoreactive LHRH (IR-LHRH), LH and PRL using previously established radioimmunoassay procedures. Three patients showed a significant rise in mean IR-LHRH plasma levels coincident with a significant decrease in mean PRL concentrations five days to two weeks following BRCR therapy, whereas mean LH titers increased significantly in only one patient. One patient showed no increase in IR-LHRH or LH with BRCR therapy and failed to show a decrease in serum PRL to normal levels after five days of this treatment. A defect in the control of PRL release in these patients seemed to result from the inability of dopaminergic inhibition to be mediated effectively and seemed to be associated with altered secretion of LHRH.
有证据表明，高催乳素血症-闭经综合征患者催乳素（PRL）分泌异常是由于下丘脑功能障碍所致。为了进一步明确过量PRL释放对人血浆中促黄体生成素释放激素（LHRH）和促黄体生成素（LH）分泌模式的抑制作用，对4名已知患有高催乳素血症的闭经女性在使用溴隐亭（BRCR）治疗前和治疗期间进行了研究。使用先前建立的放射免疫分析程序，对用连续抽血泵采集的10分钟血样进行2小时分析，检测免疫反应性LHRH（IR-LHRH）、LH和PRL。3名患者在BRCR治疗后5天至2周，平均血浆IR-LHRH水平显著升高，同时平均PRL浓度显著降低，而只有1名患者的平均LH滴度显著升高。1名患者在接受BRCR治疗后，IR-LHRH或LH未升高，且在该治疗5天后血清PRL未能降至正常水平。这些患者PRL释放控制方面的缺陷似乎是由于多巴胺能抑制无法有效介导所致，且似乎与LHRH分泌改变有关。
